Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: The invention relates to a process for preparing an instant enzyme formulation; instant enzyme formulations obtainable by this process and feedstuff compositions prepared using instant enzyme formulations of the invention.

Abstract: The present invention provides methods for improving cognitive function, improving mood, and decreasing aggression in a normal adult subject, and in a subject having symptoms characteristic of a neurological disorder, by administration of a nutriceutical formulation of the invention to the subject. The invention additionally features methods of treating neurological disorders, depression, and aggression using nutriceutical formulations. Nutriceutical compositions and formulations for use in the methods of the invention, and kits containing nutriceutical compositions and formulations, are also provided.

Abstract: This inventive thickener or gellant for oil materials is characterized by comprising (A) an high molecular weight organopolysiloxane that has a polyglycerol structure-containing hydrophilic group Q and that is represented by the following structural formula (1): R3-q(R11)qSi—O—(SiR112—O)n1—(SiR11Q-O)n2—(SiR11L-O)n3—Si(R)11)qR3-q wherein R11 is a monovalent hydrocarbyl group or a hydrogen atom; L is a chain organosiloxane group, n1, n2, and n3 are numbers in the ranges 200?n1?1000, 0?n2?20, and 0?n3?50; R is a group selected from L and Q; q is an integer in the range from 0 to 3; wherein when n2=0, q is an integer in the range from 1 to 3 and at least one R is Q. The thickener or gellant exhibits an excellent compatibility with a variety of oil systems.

Abstract: Described herein is a discovery Platform Technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building.

Abstract: A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided.

Abstract: A formulation containing an active substance encapsulated within an exine shell of a naturally occurring spore, together with a protective additive which is also encapsulated within the exine shell.

Abstract: The purpose of the present invention is to provide a process for producing an aqueous solution containing a fat-soluble substance. A combination of a super dissolution aid, cyclodextrin and a fat-soluble substance or a combination of the super dissolution aid and a cyclodextrin complex of the fat-soluble substance is used for dissolving the fat-soluble substance, whereby it becomes possible to provide an aqueous solution containing the fat-soluble substance at a high concentration and an aqueous solution having improved transdermal absorbability of the fat-soluble substance contained therein.

Abstract: A pharmaceutical composition for application in human and animals, with at least one systemically and/or locally acting, topically applicable active ingredient and with at least one phospholipid, improving the transport of the active ingredient trough the cell membrane and containing a concentration of at least 60% by weight phosphatidylcholine, referring to the phospholipid, is described. The composition shows such a liquid consistency, that it is able to be sprayed as droplets or as a foam, whereas in the composition such a phospholipid is included, that additionally contains oil in a concentration of maximum 7.5% by weight besides the at least 60% by weight phosphatidylcholine.

Abstract: The invention relates to the use of an agent and a composition, respectively, comprising the following active ingredients: a) an aromatase inhibitor and/or a 5-?-reductase inhibitor, b) an antioxidant, and c) hyaluronic acid for cosmetic purposes.

Abstract: A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: The present invention is a targeted drug delivery composition composed of carrier-linked magnetic nanoparticles. Using an alternating magnetic field, nanoparticles bound to a targeted cell are selectively ruptured thereby releasing therapeutic agents at the desired site of action.

Abstract: The invention relates to a combination preparation for improving the sperm quality and capacitation of a male individual. Said combination preparation comprises effective amounts of L-carnitine, coenzyme Q10, at least one vitamin E, particularly ?-tocopherol, at least one source of zinc, especially zinc sulfate or zinc chloride, at least one source of vitamin B, particularly folic acid, at least one source of selenium, glutathione, and arginine or salts or derivatives thereof as active substances.

Abstract: Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided.

Abstract: The presently-disclosed subject matter includes polyurethane composites that include tissue component(s), as well as methods of making such composites and uses thereof. The polyurethane component can comprise a polyisocyanate prepolymer and a polyol. The tissue component can be a polysaccharide. Exemplary composites can be moldable and/or injectable, and can cure into a porous composite that provides mechanical strength and/or supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shaped areas, voids, or the like. Exemplary composites can be used for treating wounds.

Abstract: Formulations are provided for the management of weight. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as dihydroxy acetone (DHA), inositol, 5-hydroxy-L-tryptophan (5-HTP), choline, milk protein hydrolysate, and pyruvate. The compositions can be administered orally in a variety of forms and may substitute for one or more meals per day to manage weight.

Abstract: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: The present invention relates to structures that contain one or more fiber and/or nanofiber structures where such structures can be formed on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In one embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In another embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.) where such fibers and/or structures are designed to sequester, carry and/or encapsulate one or more substances.

Abstract: The present invention provides a method for stabilization of reduced coenzyme Q10 characterized by concurrently containing a propylene glycol fatty acid ester in a composition containing reduced coenzyme Q10, and a composition containing reduced coenzyme Q10 and a propylene glycol fatty acid ester as essential constituting ingredients. According to the present invention, reduced coenzyme Q10, which is useful as a food, food with nutrient function claims, food for specified health use, nutritional supplement, nutritional product, animal drug, drink, feed, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like can be stabilized especially without being made into a complicated composition.

Abstract: The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage.

Abstract: The present invention is directed to a novel poly (diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells.

Abstract: The invention provides for the use of any form of botulinum toxin, or any enzymatically active derivative thereof, to cause temporary paralysis of the muscles of the lips of the mouth to promote smoking cessation.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: A method is provided for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp and for prediction of the recurrence of the disease.

Abstract: An antimicrobial composition is provided having a mole ratio of equivalents of silver ion to equivalents of anion of greater than 1. The invention further relates to antimicrobial compositions composed of silver ions and silver salt particles. Also provided are methods for using the compositions of the invention for the treatment of a subject, and methods for conferring antimicrobial protection to an object.

Abstract: A method of controlling a physical characteristic of polymeric nanocarrier-encapsulated protein particles includes altering or selecting a weight percentage of a hydrophobic polymer block in a total amphiphilic diblock copolymer of a primary emulsion of a double emulsion, freeze-thaw technique. The primary emulsion is formed using a freeze-thaw cycle of the amphiphilic diblock copolymer and a protein having a molecular weight of up to or equal to 300,000 Da. Selection of the hydrophobic polymer block percentage alters one or more characteristics of the resulting nanoparticles, such as shape. Thus, as one aspect, a method of producing filamentous polymeric nanocarrier-encapsulated protein (i.e.

Abstract: Disclosed herein is a soft elastic capsule that includes an acid resistant, capsule shell that defines an encapsulated space having a predetermined volume, a liquid or semisolid fill comprising a first active ingredient located within the encapsulated space, and a first compressed tablet a having a minimal dimension of 2 mm, being located within the encapsulated space, unanchored to the capsule shell, and surrounded by the fill, said tablet comprising a second active ingredient that is substantially insoluble in the fill. A method of manufacturing a soft elastic capsule is also disclosed.

Abstract: The invention concerns a functional food preparation based on milk/dairy products added with botanical products containing various active principles. The milk/dairy products, which can be obtained from fresh or pasteurized animal milk, soy milk or rice milk, comprise Saccharum officinarum containing polycosanols, Monascus purpureus containing plant statins, and Glycine max containing isoflavones and coenzymes. Further components can be added to the preparation to improve its organoleptic properties. The invention also refers to the use of the preparation as a food with functional features which are useful to stabilize the cholesterol and triglycerides amount, having an antioxidant action and protective of arteries and the cardiocirculatory system.

Abstract: The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.

Abstract: A composition for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: The present invention relates to a method for stabilizing reduced coenzyme Q10, which is useful as an ingredient in good foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc., and to a composition therefor. The composition comprises reduced coenzyme Q10, a fat and oil (excluding olive oil) and/or a polyol, and doesn't substantially inhibit the stabilization of reduced coenzyme Q10. Additionally, the composition is a reduced coenzyme Q10-containing composition which comprises reduced coenzyme Q10, a polyglycerol fatty acid ester, and a fat and oil and/or a polyol.

Abstract: The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.

Abstract: A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant.

Abstract: The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.

Abstract: The present invention also relates to an anti-fouling composition comprising one or more aerogels. In one embodiment the aerogel encapsulate one or more bioactive agents. The one or more encapsulated bioactive agents can in one preferred embodiment be released from the aerogel over time. In one embodiment the encapsulated bioactive agents comprise one or more enzymes. In one preferred embodiment the anti-fouling composition comprising one or more aerogels is a coating composition.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: A cardiovascular support composition is provided comprising red yeast rice, Coenzyme-Q10, and phytosterols. A method for maintaining cardiovascular health is also provided comprising administering the composition comprising red yeast rice, Coenzyme-Q10, and phytosterols in a predefined dosage to an individual in need thereof.

Abstract: The field of the disclosure relates to microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof. Further, the field of the disclosure relates to coatings and scaffolds comprising microparticles and the processes for forming thereof.

Abstract: Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided.

Abstract: The present invention provides a lipid carrier for delivering of a bioactive substance. The lipid carrier includes a lipid layer, a positive charged polymer and a surface active polymer. The positive charged polymer and the surface active polymer are respectively distributed on the lipid layer by non-covalent bonds. The present invention also provides a pharmaceutical composition. The present invention is advantageous for delivering bioactive substance efficiently.

Abstract: A skin agent for external use and a cosmetic agent are provided, by transdermal administration of which expected actions and effects of ubiquinone derivatives, salts thereof, ubiquinones and ubiquinols are effectively obtained. The skin agent for external use includes a ubiquinone derivative or a salt thereof as an active ingredient. The ubiquinone derivative is represented by the formula (1): wherein R1 and R2 are each a hydrogen atom or a phosphoric group, at least one of R1 and R2 is a phosphoric group, and n is an integer in the range of 1 to 9.

Abstract: Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.

Abstract: Devices, methods, and compositions are described that includes an implantable device including one or more compartments. One or more pharmaceutically effective compounds stabilized in a sugar glass composition, at least one of the one or more stabilized pharmaceutically effective compounds in the sugar glass composition enclosed within the one or more compartments; and one or more reservoirs configured to provide access for one or more release agents to an interior of the sugar glass composition, wherein the one or more reservoirs are configured to controllably dispense the one or more release agents to disrupt the sugar glass composition from the interior of the sugar glass composition.

Abstract: Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g.